Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2023-10-30 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Zevra Therapeutics, Inc. It discusses a merger agreement and related proxy statement/prospectus filings, including a supplement to the proxy statement. The document is a regulatory filing that provides updates on merger-related communications and disclosures, including references to proxy materials and SEC filings. It does not contain full financial statements or detailed financial analysis itself, but rather serves as a current report to inform investors and the SEC about recent events and filings related to the merger. The presence of the Form 8-K header and the nature of the content indicate this is a Regulatory Filing (RNS) rather than a full merger filing (MA) or proxy solicitation (PSI). The document is over 13,000 characters, so it is not a brief announcement but a substantive regulatory update. Therefore, the best classification is Regulatory Filings (RNS).
2023-10-30 English
FORM 4
Director's Dealing
2023-10-11 English
Regulatory Filings 2023
Regulatory Filings
2023-10-11 English
FORM 3
Director's Dealing
2023-10-11 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content focuses on the appointment of a new President and CEO, Neil F. McFarlane, including his background, compensation details, and the resignation of a board member. This clearly relates to changes in the company's board of directors and senior management. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report or Interim Report. The document is not a proxy solicitation, earnings release, or any other category. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2023-10-10 English
424B3
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy statement/prospectus related to a proposed merger between Acer Therapeutics Inc. and Zevra Therapeutics, Inc. It includes detailed information about the special meeting of stockholders to vote on the merger agreement, advisory votes on executive compensation related to the merger, and other related proposals. The document is filed pursuant to SEC rules (Rule 424(b)(3)) and includes a notice of meeting, voting instructions, and recommendations from the board of directors. It is not a full annual or quarterly report, earnings release, or other financial statement. It is a solicitation of shareholder votes and information related to a merger transaction. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2023-10-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.